Current and historical daily PE Ratio for CLVLF (
Clinuvel Pharmaceuticals Ltd
) from 2004 to Apr 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Clinuvel Pharmaceuticals stock (CLVLF) PE ratio as of Apr 27 2024 is 25.57.
More Details
Clinuvel Pharmaceuticals Ltd (CLVLF) PE Ratio (TTM) Chart
Clinuvel Pharmaceuticals Ltd (CLVLF) PE Ratio (TTM) Historical Data
View and export this data going back to 2004. Start your Free Trial
Total 1215
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Clinuvel Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-27 | 25.6 | 2024-02-23 | 25.6 |
| 2024-04-26 | 25.6 | 2024-02-22 | 25.6 |
| 2024-04-25 | 25.6 | 2024-02-21 | 27.5 |
| 2024-04-24 | 25.6 | 2024-02-20 | 27.3 |
| 2024-04-23 | 25.2 | 2024-02-16 | 25.8 |
| 2024-04-22 | 24.8 | 2024-02-15 | 26.9 |
| 2024-04-19 | 24.8 | 2024-02-14 | 26.9 |
| 2024-04-18 | 24.8 | 2024-02-13 | 26.6 |
| 2024-04-17 | 24.8 | 2024-02-12 | 26.6 |
| 2024-04-16 | 24.8 | 2024-02-09 | 26.6 |
| 2024-04-15 | 24.8 | 2024-02-08 | 26.4 |
| 2024-04-12 | 25.1 | 2024-02-07 | 26.4 |
| 2024-04-11 | 25.1 | 2024-02-06 | 26.4 |
| 2024-04-10 | 22.9 | 2024-02-05 | 26.4 |
| 2024-04-09 | 22.9 | 2024-02-02 | 26.4 |
| 2024-04-08 | 22.9 | 2024-02-01 | 26.4 |
| 2024-04-05 | 22.9 | 2024-01-31 | 26.4 |
| 2024-04-04 | 22.9 | 2024-01-30 | 26.4 |
| 2024-04-03 | 22.9 | 2024-01-29 | 26.4 |
| 2024-04-02 | 22.9 | 2024-01-26 | 25.9 |
| 2024-04-01 | 22.9 | 2024-01-25 | 28.8 |
| 2024-03-28 | 22.9 | 2024-01-24 | 28.8 |
| 2024-03-27 | 22.9 | 2024-01-23 | 28.8 |
| 2024-03-26 | 22.9 | 2024-01-22 | 28.8 |
| 2024-03-25 | 22.9 | 2024-01-19 | 28.8 |
| 2024-03-22 | 22.9 | 2024-01-18 | 28.8 |
| 2024-03-21 | 22.9 | 2024-01-17 | 28.8 |
| 2024-03-20 | 22.9 | 2024-01-16 | 28.8 |
| 2024-03-19 | 22.9 | 2024-01-12 | 28.8 |
| 2024-03-18 | 22.9 | 2024-01-11 | 28.8 |
| 2024-03-15 | 22.9 | 2024-01-10 | 28.8 |
| 2024-03-14 | 22.9 | 2024-01-09 | 26.9 |
| 2024-03-13 | 22.9 | 2024-01-08 | 27.4 |
| 2024-03-12 | 22.9 | 2024-01-05 | 27.4 |
| 2024-03-11 | 22.9 | 2024-01-04 | 27.4 |
| 2024-03-08 | 22.9 | 2024-01-03 | 27.4 |
| 2024-03-07 | 23.2 | 2024-01-02 | 27.4 |
| 2024-03-06 | 23.2 | 2023-12-29 | 27.4 |
| 2024-03-05 | 23.2 | 2023-12-28 | 27.4 |
| 2024-03-04 | 22.3 | 2023-12-27 | 28.9 |
| 2024-03-01 | 22.3 | 2023-12-26 | 28.9 |
| 2024-02-29 | 22.3 | 2023-12-22 | 28.9 |
| 2024-02-28 | 25.6 | 2023-12-21 | 28.9 |
| 2024-02-27 | 25.6 | 2023-12-20 | 28.9 |
| 2024-02-26 | 25.6 | 2023-12-19 | 28.9 |
Clinuvel Pharmaceuticals Ltd (CLVLF) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Clinuvel Pharmaceuticals Ltd
ISIN : AU000000CUV3
Share Class Description:
CLVLF: Ordinary SharesCompare
Compare
Traded in other countries / regions
CUV.AustraliaCLVLY.USAUR9.Germany IPO Date
2004-06-16Description
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers